To investigate the associations between ocular discomfort, compliance and efficacy of IOP lowering drugs. METHODS: This was a prospective observational survey. Centres were selected at random from the CEGEDIM list. Consecutive patients treated with an IOP lowering fixed combination drug (prostaglandin analogues excluded) were included. IOP was collected at two visits (delay fixed by the investigator). Self-reported compliance measured by validated questionnaires (EDSQ, TSQM and TEO) and self-reported ocular discomfort (13 items with a focus at instillation and during the day) based on a questionnaire developed according to international patient reported outcome recommendations were collected at the last visit. Patients were classified into 3 groups of compliance (good, minor and major issues) using the TEO published algorithm. Comparisons between compliance groups were made by ANOVA and chi-square tests. Adjustments were made for confounding variable unbalances. RESULTS: 410 patients (66 years old, 237 females, 101 ocular hypertensions) were included. 32.9% reported good compliance, 55.9% minor and 11.2% major compliance issues. Patients reporting either red eyes (Pϭ0.02), stinging (Pϭ0.007), feeling of sand in the eyes (Pϭ0.0009), dry eye (Pϭ0.02), or blurry vision (Pϭ0.002) were more likely to report compliance issues. Patients in the good compliance group reported 3.2 ocular discomfort concerns, 4.5 in the minor and 5.2 in the major compliance issue group (Pϭ0.0002). The probabilities to report no concern were 24.2%, 12.7% and 11.9% (Pϭ0.02), respectively. An association between IOP control and compliance was reported in the group of patients that did not have a change in treatment at the first visit: patients in the good compliance group had an IOP decrease of 0.9 mmHg, 0.3 mmHg in the minor and a 0.2 mmHg increase in the major compliance issue group. CONCLUSIONS: Ocular discomfort issues reported by patients might impact compliance leading to poor IOP control.
OBJECTIVES:
To determine the prevalence, demographics and treatment characteristics of patients with visual impairment (VI) due to diabetic macular edema (DME) in a real-world Canadian setting. METHODS: Records from a longitudinal population-based database of more than 170,000 patients in 53 family practice clinics in southwestern Ontario, Canada were analyzed between January 1, 2008 to December 31, 2009 . Patient records were limited to those aged 18 years of age and older. These records contained chart-abstracted information such as visit diagnosis, medications and consultation notes. Initial extractions of control, diabetic and DME patients with VI, defined as best corrected visual acuity Յ20/40 in the DME eye, were accomplished utilizing International Classification of Disease codes (ICD9/ ICD10); reviewing patient charts for text entries of symptoms that supported a diagnosis of diabetes and DME and concomitant comorbidity; and reviewing patient treatment records unique to DME with VI including consultation notes and hospital discharge summaries. Demographic characteristics, comorbidities, and treatment were reported. RESULTS: 8368 patients with type 1 or 2 diabetes and a control cohort of 76,077 patients were extracted for this analysis. Among diabetic patients, prevalence of DME was 15.7%. Average duration of diabetes among patients with DME was 19 years. More patients with DME had hypertension (66%), or vascular disease (28%) than the control cohort (pϽ0.05). The prevalence of VI due to DME was 2.56%. Mean age was 64Ϯ17. In patients with VI due to DME, 53% had focal and 47% had diffuse edema. For both focal and diffuse edema, the most common treatment was laser monotherapy, used in 62% and 53% of cases, respectively. CONCLUSIONS: : In a real-world setting, among patients with diabetes, we observed the prevalence of VI due to DME at 2.56% . Laser monotherapy was the most common treatment. 
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INCIDENCE AND CHARACTERISTICS OF PATIENTS WITH MACULAR EDEMA SECONDARY TO RETINAL VEIN OCCLUSION IN A REPRESENTATIVE CANADIAN COHORT
OBJECTIVES:
Retinal vein occlusion (RVO) has an abrupt onset and is an important cause of visual morbidity. Macular edema (ME) is the most common cause of visual impairment (VI) in patients with RVO. The Canadian incidence of VI due to ME secondary to RVO is unknown. This study aimed to determine the annual incidence and characteristics of patients with ME secondary to branch RVO (BRVO) and central RVO (CRVO) in a real-world Canadian setting. METHODS: Records from a lon-gitudinal population-based database of more than 170,000 patients in 53 family practice clinics in southwestern Ontario, Canada were analyzed between January 1, 2008 and December 31, 2009. These records contained chart-abstracted information such as visit diagnosis, medications and consultation notes. Initial extractions of control cohort and RVO patients with ME and VI (defined as best corrected visual acuity Յ20/40 in the RVO eye), were accomplished utilizing International Classification of Disease codes (ICD9/ICD10); reviewing patient charts for text entries of symptoms that supported a diagnosis of RVO and concomitant comorbidity; and reviewing patient treatment records unique to RVO including consultation notes and hospital discharge summaries. Demographic characteristics and comorbidities were reported. RESULTS: Seventy-three (53 with BRVO and 20 with CRVO) of 47,166 patients over 40 years (mean age 61Ϯ17 years) with new diagnosis of RVO and a control cohort of 76,077 patients were extracted for this analysis. The annual incidence of VI due to ME secondary to BRVO and CRVO was 0.056% and 0.021%, respectively. More RVO patients had hypertension (68 vs. 18%) or dyslipidemia (16 vs. 10%) than control cohort (pϽ0.05). One-quarter of RVO patients had a history of vascular disease, primarily MI and stroke. CONCLUSIONS: In a real-world setting, the annual incidence of VI due to ME secondary to BRVO and CRVO was 0.056% and 0.021%, respectively. RVO is associated with several vascular comorbidities. 
PSS4 LONGER TERM PATIENT BENEFITS OF POLYQUAD® PRESERVATIVE INSTEAD OF BENZALKONIUM CHLORIDE IN PROSTAGLANDIN EYE DROPS: A MICROSIMULATION MODEL IN OCULAR HYPERTENSION AND OPEN-ANGLE GLAUCOMA
OBJECTIVES:
The presence of the preservative benzalkonium chloride (BAK) at 0.01% concentration in commercialized prostaglandin eye drops for glaucoma is known to increase the risk of ocular surface disease (OSD), which worsens with the extent of exposure to BAK. We aimed to estimate longer term clinical outcomes with travoprost preserved with Polyquad® 0.001% instead of BAK. METHODS: A Markov microsimulation model was developed (TreeAge) to assess the development of OSD and disease progression (Mean Defect [MD], in db) over 10 years, in patients initiating travoprost with Polyquad® followed by travoprost/beta-blocker fixed combination vs. the same sequence using BAK-preserved drops. Initial patient's characteristics came from distributions on age (normal), sex, OSD presence, disease stage (uniform) and anticipated progression rates (triangular). The risk of developing OSD in aging population was derived from a US incidence study, multiplied by independent risk factors (age, sex, duration and amount of BAK-containing drops received). Rates of disease progression (db/year) came from landmark studies in OHT/glaucoma, multiplied by independent accelerating factors (disease stage, treatment line, OSD severity, non-compliance). Compliance was expected by experts to be 20% (absolute) better with Polyquad® vs. BAK-preserved drops. RESULTS: Using 3000 trials (mean age 57 years, 57% female, 14% with initial OSD, mean MD -4db), 47.6% [41.5-53.6%] of patients receiving in first and second line BAK-preserved travoprost treatments are expected to have OSD at 10 years versus 31.7% [28.5-35.1%] with Polyquad®. In OHT/early glaucoma patients, the model predicted the progression to advanced glaucoma (MDϽ-12db) of 13.2% [12.0-14.4%] with Polyquad® versus 18. 1% [16.7-19 .5%] with BAK. In patients diagnosed with moderate glaucoma, 1.9% [1.4-2.4%] versus 5.6% [4.8-6.4%] progressed to blindness (MDϽ-24db) respectively. CONCLUSIONS: The model estimated that OSD incidence was reduced by 33% and glaucoma disease progression was significantly less frequent after 10 years of use of Polyquad® versus BAK-containing travoprost eye drops. 
PSS5 VISUAL FIELD EVOLUTION IN GLAUCOMA PATIENTS PRESENTING WITH DIFFERENT DISEASE STAGES: RESULTS FROM AN OBSERVATIONAL STUDY
OBJECTIVES:
The progression of glaucoma is measured by a Mean Defect (MD) of the perimetry in decibels (db), from an early disease stage (Ͻ6db loss), until moderate (6-12db loss), advanced stages (12-24db loss) and eventually blindness (Ͼ24db loss). The rate of disease progression is highly variable between individuals and hard to predict. The objective of this study was to analyze the change in MD of glaucoma patients in a real-life setting in Germany. METHODS: We analyzed patient-level data from a German observational study in ocular hypertension (OHT) and glaucoma, with retrospective collection of MD measures (db). Descriptive statistics were derived on the rate of disease progression (db loss/year, obtained by dividing the change in MD by the duration of observation). The change in MD in best eye between the time of first treatment until last MD measure was included in a generalized linear regression, adjusting for age, sex, presence of cataract, time since first treatment, initial MD and initial glaucoma stage (OHT, early/moderate or advanced). RESULTS: MD data was available for 57 patients (53% female, mean age 67 ϩ/Ϫ12 years). The mean (SD) time from first treatment until last MD measure was 7.0 (3.7) years. The mean (SD) MD was -4.5db (4.7) at first treatment and -6.0db (6.8) at last assessment (i.e. average rate of progression of -0.21db/year, all stages). In 12 OHT patients, 50% had no MD worsening, while 50% lost on average -0.26db/ year. Based on the adjusted analysis, the initial diagnosis was significantly associated with the amount of db loss over time (early/moderate glaucoma -0.19db/year ϩ/Ϫ0.13, advanced -0.66db/year ϩ/Ϫ0.22, pϭ0.038). CONCLUSIONS: The rates of disease progression measured over more than 7 years in glaucoma patients was significantly increasing with their initial disease severity. Amount of db loss per year were in line with previously published prospective studies. Sookmyung Women's University, Seoul, South Korea OBJECTIVES: The objective of this study was to summarize epidemiology, disease burden, symptomatology, treatment pattern, and quality of life in macular degeneration (MD) in the Korean population through a systematic literature review. METHODS: Literature searches were conducted through Korean databases(RISS, KMBase, KoreaMed, NDSL, National Assembly Library), national statistics portals and ophthalmology journals for the period to April 2011, using Љmacular degener-ationЉ as a keyword. Publications were selected according to pre-defined selection criteria. RESULTS: Forty-three studies were identified and included in the review. Most (40) described clinical characteristics and treatment pattern. 4 described epidemiology and 2 focused on quality of life. No study estimated economic burden. In summary, 1) MD characterizes exudative form, subretinal neovascularization or retinal pigment epithelial detachment, and equal distribution of circular and geographic atrophy; 2) MD is a major reason of low vision/visual impairment; 3) Drug therapy such as bevacizumab or ranibizumab presents effects on decrease of central macular thickness and preservation of visual acuity, but optimized patients have to be identified. Photodynamic therapy is relatively safe, and pneumatic displacement or radiation therapy is somehow effective on visual acuity even though being a risk of vision loss. Concurrent drug and non-drug therapies have been tried as well clinically; 4) Prevalence of MD is higher in elderly over 65 years with 13.3% rate and higher proportion of exudative form than western countries; and 5) Quality of life is decreased in patients with MD or low vision. CONCLUSIONS: This study describes lack of local information especially disease burden and quality of life. In the era growing sharply aging population, prevent and treat MD are crucial for preserving vision and improving quality of life. Therefore future studies are needed. OBJECTIVES: Diabetic macular edema (DME) is the main cause of visual impairment (VI) in diabetic patients. The prevalence of DME is estimated to be 5.4% in Europe, but there is no observational evidence currently available. The objective was to determinate the prevalence of DME and DME with VI from Belgium, France, Germany, Italy, The Netherlands, Spain and UK, in an epidemiological study. Reported here are the results from Spain. METHODS: Patients with diabetes mellitus types 1 and 2 (DM1 and DM2) were consecutively recruited by General Practitioners (GPs) across Spain. Diagnosis and severity of DME, related VI, sociodemographics, general and ophthalmic comorbidities, HbA1c, antidiabetic and DME treatment were documented. Patients with retinitis pigmentosa, epiretinal membrane, or active uveitis were excluded from the calculation of VI due to DME. RESULTS: A total of 26 GPs recruited 445 eligible patients (38 DM1, 411 DM2) from July 2010 to April 2011, 51.2% male, mean (SD) age of 66.2 (12.8) years, 37.2% smokers or exsmokers. Patients with DME diagnosis showed a longer length of time since onset of diabetes (14.55 y vs 9.64). The prevalence of DME was estimated to be 4% (18/445 patients) (95%CI 2.2-5.8%) and VI due to DME was 2% (9/445) (95%CI 0.7-3.3%). Poor diabetic control (HbA1c Ն7%) was reported in 219 (48.8%) of all patients, being higher in those with DME (66.7%). Ocular comorbidities, such as cataract or glaucoma, were present in 17 (94.4%) DME patients. 15 (83.3%) patients received DME treatment, mainly laser photocoagulation (77.8%), alone or in combination with vitrectomy and/or pharmacological treatment. CONCLUSIONS: ME affects 4% of the diabetic patients in Spain, and 2% of them suffer VI due to DME. Results suggest that poor diabetic control and long time since diabetis onset are associated with development of DME. This study was sponsored by Novartis Pharma AG.
PSS6 EPIDEMIOLOGY, DISEASE BURDEN, SYMPTOMATOLOGY, TREATMENT PATTERN, AND QUALITY OF LIFE IN MACULAR DEGENERATION IN KOREA: SYSTEMATIC LITERATURE REVIEW BASED ON KOREAN EVIDENCE
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PSS7 PREVALENCE ASSESSMENT OF DIABETIC MACULAR EDEMA WITH VISUAL IMPAIRMENT IN SPAIN: A PREVAIL STUDY
PSS8 ADVANCED CUTANEOUS MELANOMA IN THE UK: A SYSTEMATIC REVIEW
Poku E 1 , Cooper K 1 , Wang Q 2 , Bapat U 2 , Lebmeier M 2 1 University of Sheffield, Sheffield, South Yorkshire, UK, 2 Bristol-Myers Squibb, Uxbridge, Middlesex, UK OBJECTIVES: Cutaneous malignant melanoma (CMM) is an uncommon yet aggressive form of skin cancer. In 2008, CMM was found to be the sixth most common cancer in the UK. The aim of this review was to identify the incidence of advanced CMM in the UK (UK). The definition of advanced CMM was stage IIIc and stage IV disease in affected patients. METHODS: Multiple sources including the Cochrane Library, MEDLINE, EMBASE and CINAHL were searched between December 2010 and March 2011. Searches were also conducted by scanning the websites of the Office of National Statistics, Cancer Research UK as well as the Welsh Cancer Intelligence and Surveillance Unit. A narrative synthesis was undertaken due to heterogeneity in included studies. RESULTS: Of the three included studies, 2 were conducted in Scotland while one was undertaken in the East Anglia region of England. Although all patients had a confirmed diagnosis of CMM, variations in staging methods and unclear or insufficient reporting made it challenging to identify patients with stage IIIc and stage IV disease. Both studies undertaken in Scotland at different periods reported that 2% of all melanoma patients had advanced CMM at the time of diagnosis. However, the definitions of advanced CMM were not similar in each study. The incidence of stage IV CMM reported in 3,971 patients from East Anglia decreased from 0.42 to 0.13 per 100,000 population per year between 1991 and 2004. CONCLUSIONS: This review highlighted the lack of, and need for primary studies to estimate the incidence of advanced CMM in the UK. In order to examine trends across UK as well as identify patients for targeted treatment, we suggest that researchers must clearly define this sub-group in future studies.
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PSS9 THE BURDEN OF AGE-RELATED MACULAR DEGENERATION IN THE NETHERLANDS
Boland MRS 1 , Vingerling J 2 , Groot M 3 , Hakkaart-van Roijen L 1 1 Erasmus University, Rotterdam, The Netherlands, 2 Erasmus Medical Center, Rotterdam, Rotterdam, The Netherlands, 3 Novartis Pharma B.V., Arnhem, The Netherlands OBJECTIVES: Age-Related Macular Degeneration (AMD) is a disorder of the central area of the retina resulting in a significant loss of visual acuity. AMD is the leading cause of incurable blindness and visual impairment in industrialized countries. Consequently AMD leads to decrease of Quality of Life (QoL) and increased health care costs. For the The Netherlands no information on the burden of AMD was available. The main aim of this study was to assess the burden of AMD patients in the The Netherlands in terms of health care costs and QoL from a societal perspective. METHODS: AMD cost parameters were identified and the 'AMD cost and impact questionnaire' was developed. Members of the Dutch Macular Degeneration Patient Organization with a disease severity ranging from normal vision to legally blind were invited to enter the study during regional meetings. The EuroQol 5D was used for measuring QoL. Data on resource use and QoL were collected through telephone interviews. RESULTS: Seventy-five patients completed the questionnaire. The average total annual cost for AMD was €5651 per person (95% CI: 4252 -7051). Home help was the major cost component (€2507 p.p.). Total costs were significantly higher for individuals with more severe AMD and the QoL significantly lower for individuals with more severe AMD (PϽ0.05). The average utility of AMD was 0.792 (95% CI: 0.771-0.812) significantly lower than the average 50ϩ Dutch population (0.850). The respondents reported 'usual activities' as the area with the most problems. CONCLUSIONS: Increased visual impairment leads to significantly higher annual costs and lower overall QoL. 
PSS10 ECONOMIC OUTCOMES OF GLAUCOMA TREATMENT WITH PROSTAGLANDIN EYE DROPS PRESERVED WITH POLYQUAD® INSTEAD OF BENZALKONIUM CHLORIDE IN GERMANY
OBJECTIVES:
In glaucoma patients, the long term use of prostaglandin eye drops containing benzalkonium chloride (BAK) increases the risk of developing an ocular surface disease (OSD). Polyquad® preserved prostaglandins are now available, among which travoprost proved similar in efficacy and safety compared to BAKpreserved formulations. We aimed to estimate the impact of Polyquad® instead of BAK on glaucoma management cost. METHODS: A Markov microsimulation model was developed in TreeAge, including 5 health states corresponding to 4 treatment lines plus death, in representative, treatment-naive patients at different OHT/glaucoma stages. The sequence travoprost-travoprostϩtimolol fixed combination preserved with Polyquad® was compared to BAK-preserved latanoprostlatanoprostϩtimolol (LAT) and bimatoprost-bimatoprostϩtimolol (BIM). The model events were: onset of OSD (risk factors: age, sex, BAK exposure; sources: US incidence study [Moss 2005], Erb 2008), need for treatment change including surgery/laser (risk factors: treatment line, disease stage, OSD presence, BAK exposure; sources: persistence studies in UK GPRD [Lafuma 2007] and US claims database [Schmier 2010]), and disease progression (risk factors: treatment line, OSD severity, non-compliance; sources: large prospective studies in OHT/glaucoma). Costs data came from a German observational study in OHT/glaucoma with 5-year retrospective collection of medical resources used (Statutory Health Insurance perspective ϩ patient co-payments; 2011 drug costs, other costs 2010). The 95% confidence intervals came from a probabilistic sensitivity analysis. RESULTS: After 10 years, the total management cost in the travoprost with Polyquad® arm was €4677 [4378; 5013] compared to €5196 [4904;5482] with LAT and €5342 [5069;5664] with BIM. More patients required eye surgery/laser procedures with BAK-preserved sequences (LAT: 4.7% [3.2;6.4%], BIM: 6.0% [4.0;8.3%]) compared to travoprost with Polyquad® (1.8% [0.9;2.9%]). CONCLUSIONS: At 10 years, prostaglandin treatment with Poly-quad® is expected to reduce the cost of glaucoma treatment by 10-15% from both individual and societal perspectives, and have lower surgery/laser rates compared to BAK-preserved treatments. 
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RANIBIZUMAB AND BEVACIZUMAB FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION: A SYSTEMATIC REVIEW AND ECONOMIC EVALUATION
